(Q42952349)

11 November 2017

title

Hepatitus B virus reactivation in HBV-DNA negative and positive patients with hematological malignancies (English)

1 reference

11 November 2017

Münci Yağci

1

1 reference

11 November 2017

Zübeyde Nur Ozkurt

2

1 reference

11 November 2017

Zeynep Arzu Yeğin

3

1 reference

11 November 2017

Zeynep Aki

4

1 reference

11 November 2017

Gülsan Türköz Sucak

5

1 reference

11 November 2017

Rauf Haznedar

6

1 reference

11 November 2017

publication date

1 August 2010

1 reference

11 November 2017

1 reference

11 November 2017

volume

15

1 reference

11 November 2017

issue

4

1 reference

11 November 2017

page(s)

240-244

1 reference

Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors

11 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12583347114059

Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12583347114059

Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12583347114059

A prospective study on chemotherapy-induced hepatitis B virus reactivation in chronic HBs Ag carriers with hematologic malignancies and pre-emptive therapy with nucleoside analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12583347114059

Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12583347114059

High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12583347114059

Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12583347114059

High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12583347114059

Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12583347114059

Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12583347114059

Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12583347114059

Hepatitis B virus infection and B-cell non-Hodgkin's lymphoma in a hepatitis B endemic area: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12583347114059

Prevalence of hepatitis B or C virus infections in patients with non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12583347114059

Hepatitis B and C virus infection in Romanian non-Hodgkin's lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12583347114059

Occult hepatitis B virus infection of peripheral blood mononuclear cells among treatment-naive patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12583347114059

Molecular virology of hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12583347114059

Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12583347114059

Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12583347114059

The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12583347114059

Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12583347114059

Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy--a prospective case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12583347114059

Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12583347114059

Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12583347114059

Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12583347114059

Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12583347114059

Reactivation of hepatitis B virus infection with cytotoxic therapy in non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12583347114059

Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12583347114059

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12583347114059

Four years of lamivudine treatment in Chinese patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12583347114059

10.1179/102453309X12583347114059

21 January 2018

Identifiers

DOI

1 reference

11 November 2017

1 reference